Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy.

ABSTRACT:

Background

Immunotherapy has emerged as a crucial treatment modality for solid tumours, yet tumours often evade immune surveillance. There is an imperative to uncover novel immune regulators that can boost tumour immunogenicity and increase the efficacy of immune checkpoint blockade (ICB) therapy. Epigenetic regulators play critical roles in tumour microenvironment remodelling, and N6-methyladenosine (m⁶A) is known to be involved in tumourigenesis. However, the role of m⁶A in regulating T-cell function and enhancing anti-tumour immunity remains unexplored.

Methods

Several cancer cell lines were treated with STM2457, an enzymatic inhibitor of RNA m⁶A methyltransferase METTL3, and explored the transcriptome changes with RNA sequencing (RNA-seq)

SUBMITTER: Wu K 

PROVIDER: S-EPMC11578931 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature